Biochoices invests $75K to expand hormone product manufacturing
A $75,000 capital investment in equipment and manufacturing infrastructure is supporting the expansion of Biochoices, a local manufacturer of over-the-counter bioidentical hormone replacement products aimed at women experiencing menopause and perimenopause.
The investment financed a dedicated manufacturing room and new production equipment, which the company presented during a soft opening in San Juan attended by representatives from the public and private sectors.
Company officials used the event to outline Biochoices’ growth, business plans and the role its products play in women’s hormonal health in Puerto Rico.
“The company was born after more than 15 years working as a pharmacist formulating customized bioidentical hormones and listening to hundreds of women’s stories, seeking to create something safe, accessible and science-based,” said founder and licensed pharmacist Nimia I. Vázquez-Suárez.
Vázquez-Suárez said Biochoices increased sales from $3,000 in 2024 to $91,000 in 2025, an expansion she said has supported up to seven direct and indirect jobs.
The company develops and manufactures several hormone-support creams. Its progesterone cream is intended to address symptoms associated with low progesterone levels, which are common during perimenopause.
Prog-Estrofem is formulated for women in menopause, while other products include Hydra-V, focused on intimate wellness and hydration, and Vibido, aimed at supporting libido. A product for male hormonal wellness is in development, according to the company.
Vázquez-Suárez, who has more than 30 years of experience as a pharmacist, said the product line is based on her background in compounding prescription hormone replacement medications and adapting that experience to commercial formulations.
“These products address progesterone and estrogen deficiencies and are created with high-quality equipment and the highest manufacturing standards, allowing us to produce up to 1,500 units annually,” she said.
Vázquez-Suárez said some women lack access to specialized medical services, while others prefer not to use prescription hormone therapies or cannot afford customized medications.
More than 200,000 women in Puerto Rico are between the ages of 45 and 55, which Vázquez-Suárez described as a key stage for menopause and perimenopause. During 2025, the company served 75 women through product sales, education and personalized guidance.
Looking ahead, Biochoices projects reaching 7,800 women over the next three years from an estimated local market of 97,500. Company officials said an export and marketing strategy is expected to expand its reach, particularly among stateside Hispanic consumers.
Vázquez-Suárez credited Grupo Guayacán with supporting the company through a health-sector grant awarded in 2024.
She said the funds were reinvested in business development and marketing, and that Biochoices plans to expand its sales and distribution network and introduce three to four men’s health products.
Biochoices distributes its products through physical outlets, health fairs and educational events, with a focus on consumer education.
Representatives from the Department of Economic Development and Commerce, Hecho in Puerto Rico, the Puerto Rico Manufacturing Extension and Grupo Guayacán attended the event.
